1116 UK MHRA NICE
BioCentury & Getty Images

Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

New MHRA pathways and a greater risk tolerance at NICE could make the U.K. an attractive destination for drug developers

New MHRA pathways and a greater risk tolerance at NICE could make the U.K. an attractive destination for drug developers.

Nov 14, 2020 | 2:03 AM GMT

On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient access to new medicines. Doing so will require aligning the risk appetites of the regulator MHRA, the HTA body NICE, and NHS England — anything short of this would likely result in a continuation of the same access challenges that have hindered access to new medicines over the past two decades.

With about six weeks to go before the U.K. officially leaves the EU, there are real opportunities and ambition for a step change in how the U.K. approves and pays for new drugs.

U.K. regulator Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on a set

Read the full 1902 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE